Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst

The multiple sclerosis field has been a hotbed for payers pressing drugmakers to trade formulary spots for discounts. But that’s changed a bit in 2018—and that means some MS-dependent companies can breathe a big sigh of relief.